Semaglutide Heart Benefits May Extend Beyond Weight Loss

How Does Semaglutide Reduce Cardiovascular Risk?

SELECT enrolled 17,604 adults aged 45 or older who had established cardiovascular disease and a body mass index of at least 27 but did not have diabetes. Participants received once-weekly semaglutide 2.4 mg or placebo alongside usual medical care. Over approximately 40 months of follow-up, cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred 20% less often in the semaglutide group.

Weight reduction probably contributed to the benefit, but it may not explain the entire effect. GLP-1 receptor agonists can improve blood pressure, blood glucose regulation, lipid profiles, and inflammatory signaling. These changes may slow atherosclerotic disease or make existing plaques less likely to trigger a heart attack or stroke, although researchers are still determining how much each mechanism contributes.

Can Semaglutide Prevent Infections?

A later SELECT analysis reported fewer deaths from noncardiovascular causes among participants receiving semaglutide, with infection-related deaths contributing to the difference. During the COVID-19 pandemic, semaglutide did not appear to prevent people from becoming infected, but serious outcomes after infection were less frequent among treated participants.

This distinction is essential: a reduction in infection-related mortality is not proof of an antimicrobial or immune-boosting effect. Improved cardiometabolic health may make severe illness easier to withstand, while reduced inflammation or other biological effects could also play a role. Because infection outcomes were not the trial's primary endpoint, the finding should be viewed as an important signal requiring dedicated research.

Who May Benefit From Semaglutide for Heart Protection?

Based on SELECT, the US Food and Drug Administration expanded the indication for Wegovy in 2024 to reduce cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. The result should not automatically be extrapolated to younger people, adults without established cardiovascular disease, or people whose body weight falls outside the studied range.

Treatment decisions require an individualized assessment of cardiovascular risk, gastrointestinal adverse effects, gallbladder and pancreatic concerns, pregnancy plans, other medicines, and access to long-term care. Semaglutide complements rather than replaces established measures such as smoking cessation, physical activity, blood-pressure treatment, cholesterol management, and appropriate antiplatelet therapy.